Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration

FLT3-ITD–mediated leukemogenesis is associated with increased expression of oncogenic PIM serine/threonine kinases. To dissect their role in FLT3-ITD–mediated transformation, we performed bone marrow reconstitution assays. Unexpectedly, FLT3-ITD cells deficient for PIM1 failed to reconstitute lethally irradiated recipients, whereas lack of PIM2 induction did not interfere with FLT3-ITD–induced disease. PIM1-deficient bone marrow showed defects in homing and migration and displayed decreased surface CXCR4 expression and impaired CXCL12–CXCR4 signaling. Through small interfering RNA–mediated knockdown, chemical inhibition, expression of a dominant-negative mutant, and/or reexpression in knockout cells, we found PIM1 activity to be essential for proper CXCR4 surface expression and migration of cells toward a CXCL12 gradient. Purified PIM1 led to the phosphorylation of serine 339 in the CXCR4 intracellular domain in vitro, a site known to be essential for normal receptor recycling. In primary leukemic blasts, high levels of surface CXCR4 were associated with increased PIM1 expression, and this could be significantly reduced by a small molecule PIM inhibitor in some patients. Our data suggest that PIM1 activity is important for homing and migration of hematopoietic cells through modification of CXCR4. Because CXCR4 also regulates homing and maintenance of cancer stem cells, PIM1 inhibitors may exert their antitumor effects in part by interfering with interactions with the microenvironment.

[1]  M. Nawijn,et al.  Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. , 2006, Cancer research.

[2]  P. Meltzer,et al.  Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. , 2005, Blood.

[3]  Kwang-Hoon Chun,et al.  PKCδ modulates p21WAF1/CIP1 ability to bind to Cdk2 during TNFα-induced apoptosis , 2006 .

[4]  R. Gorlin,et al.  Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.

[5]  J. Juarez,et al.  CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment , 2007, Leukemia.

[6]  H. Kantarjian,et al.  Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. , 2005, Current molecular medicine.

[7]  P. Koskinen,et al.  Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.

[8]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[9]  P. Klasse,et al.  Chemokine receptor trafficking and viral replication , 1999, Immunological reviews.

[10]  Stefan Knapp,et al.  Structure and Substrate Specificity of the Pim-1 Kinase* , 2005, Journal of Biological Chemistry.

[11]  M. Ratajczak,et al.  The pleiotropic effects of the SDF-1–CXCR4 axis in organogenesis, regeneration and tumorigenesis , 2006, Leukemia.

[12]  J. Field,et al.  p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association* , 2005, Journal of Biological Chemistry.

[13]  P. Hammerman,et al.  Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. , 2005, Blood.

[14]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[15]  Y. Chalandon,et al.  Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. , 2005, Haematologica.

[16]  S. Koschmieder,et al.  Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation , 2008, Leukemia.

[17]  Chunaram Choudhary,et al.  Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.

[18]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[19]  F. Sigaux,et al.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[21]  N. Magnuson,et al.  Pim-1 Kinase-Dependent Phosphorylation of p21Cip1/WAF1 Regulates Its Stability and Cellular Localization in H1299 Cells , 2007, Molecular Cancer Research.

[22]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[23]  B. Löwenberg,et al.  Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. , 2004, Blood.

[24]  Kyu-Tae Kim,et al.  Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1 , 2006, British journal of haematology.

[25]  N. Warrington,et al.  Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. , 2005, Cancer research.

[26]  P. Laird,et al.  Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells. , 1993, Blood.

[27]  C. Miething,et al.  FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. , 2005, Blood.

[28]  Jos Jonkers,et al.  Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.

[29]  C. Martínez-A,et al.  Chemokines integrate JAK/STAT and G‐protein pathways during chemotaxis and calcium flux responses , 2003, European journal of immunology.

[30]  E. Estey,et al.  Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias , 2006, Molecular Cancer Therapeutics.

[31]  J. Juarez,et al.  SDF-1 and CXCR4 in normal and malignant hematopoiesis. , 2004, Histology and histopathology.

[32]  M. Le Bousse-Kerdilès,et al.  Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. , 2002, Blood.

[33]  Anton Berns,et al.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.

[34]  A. Miyajima,et al.  Suppression of interleukin‐3‐induced gene expression by a C‐terminal truncated Stat5: role of Stat5 in proliferation. , 1996, The EMBO journal.

[35]  M. Lübbert,et al.  CXCR4 is a prognostic marker in acute myelogenous leukemia. , 2007, Blood.

[36]  Arnon Nagler,et al.  CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. , 2004, Cancer research.

[37]  M. Loh,et al.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.

[38]  A. Allan,et al.  Cancer stem cells: implications for the progression and treatment of metastatic disease , 2007, Journal of cellular and molecular medicine.

[39]  H. Janssen,et al.  Synaptotagmin 3 deficiency in T cells impairs recycling of the chemokine receptor CXCR4 and thereby inhibits CXCL12 chemokine-induced migration , 2007, Journal of Cell Science.

[40]  J. Benovic,et al.  Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.

[41]  C. Peschel,et al.  Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back , 2003, Leukemia.

[42]  S. Mundell,et al.  Trafficking of the HIV Coreceptor CXCR4 , 1999, The Journal of Biological Chemistry.

[43]  G. Downey,et al.  L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. , 2003, Blood.